Research articles
ScienceAsia 51 (2023): 1-9 |doi:
10.2306/scienceasia1513-1874.2023.081
CEP170 enhances ccRCC progression by promoting platelet
aggregation and angiogenesis
Huibing Li,a,b,*, Shimiao Zhua, Qi Lia, Zongsu Zhanga, Changyi Quana,*/
ABSTRACT: CEP170 (centrosomal protein 170 kDa) is implicated in cancer progression, but its role in clear cell renal
cell carcinoma (ccRCC) remains unclear. This study explored how CEP170 drives ccRCC malignancy, revealing its
potential as a therapeutic target. Immunoblotting revealed significant upregulation of CEP170 in ccRCC cell lines, while
CCK-8 and EdU assays demonstrated that CEP170 silencing suppressed cancer cell proliferation. Functional analyses,
including immunostaining, ELISA, and flow cytometry, revealed that CEP170 depletion inhibited platelet aggregation
induced by ccRCC cells. Furthermore, tube formation and transwell assays revealed attenuated angiogenesis and
migration upon CEP170 knockdown. In vivo experiments confirmed that CEP170 silencing hindered tumor growth
in mice. Mechanistically, CEP170 activated the Twist1/galectin-3 signaling axis, as validated by immunoblotting,
thereby driving platelet aggregation, angiogenesis, and tumorinvasion. Thesefindingscollectivelyindicate thatCEP170
promotes ccRCC progression by enhancing cancer cell-stimulated platelet aggregation as well as angiogenesis via the
Twist1/galectin-3 pathway, highlighting its potential as a target in ccRCC management.
Download PDF
Downloads Views
| a |
Department of Urology, Tianjin Institute of Urology, The Secondary Hospital of Tianjin Medical University,
Hexi District, Tianjin 300211 China |
| b |
Department of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science
and Technology, Luoyang 471003 China |
* Corresponding author, E-mail: researcherlhb@163.com, quanchangyi@tmu.edu.cn
Received 17 May 2025, Accepted 11 Sep 2025
|
